Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Merz Pharmaceuticals announced today that data from stability and clinical studies evaluating Xeomin (incobotulinumtoxinA), a botulinum toxin type A free from accessory proteins, will be presented at the 71st Annual Assembly of the American Academy of Physical Medicine and Rehabilitation (AAPM&R) in Seattle, Wash.

8 Nov 2010

Athersys secures three Therapeutic Discovery Project grants

Athersys, Inc. announced today that it has secured three Therapeutic Discovery Project grants as part of the Patient Protection and Affordable Care Act of 2010. These grants were awarded related to Athersys' development of MultiStem® for the treatment of acute myocardial infarction (AMI), also known as heart attack, and other forms of cardiovascular disease, as well as for the treatment of multiple diseases causing acute tissue damage and chronic inflammation.

4 Nov 2010

'Phantom' images brain keeps for visual comparisons stored in brain's neural network

Brain research over the past 30 years has shown that if a part of the brain controlling movement or sensation or language is lost because of a stroke or injury, other parts of the brain can take over the lost function - often as well as the region that was lost.

4 Nov 2010

Gene fusion prostate cancers susceptible to secondary mutations

Scientists at Weill Cornell Medical College have taken an important step toward a better understanding of prostate cancer by uncovering evidence that it is not one disease, as previously believed, but rather several factors which can be measured and, in the future, destroyed by targeted therapy.

4 Nov 2010

New findings show combinational therapy effective for patients with DLBCL lymphoma

Diffuse large B-cell lymphoma (DLBCL) is a type of aggressive non-Hodgkin's lymphoma that accounts for approximately 40 percent of lymphomas among adults. If left untreated, it is fatal. The existing treatments have a cure rate that is slightly over 50 percent but destroy healthy cells along with the cancer cells.

4 Nov 2010

Aeolus receives $489,000 grant under QTDP program for two lead compounds

Aeolus Pharmaceuticals, Inc. today announced that it has been awarded a total of approximately $489,000 under the Qualifying Therapeutic Discovery Grant Program (QDTP) administered by the Internal Revenue Service and the Department of Health and Human Services.

4 Nov 2010

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

Safeguard Scientifics, Inc., a holding company that provides growth capital for entrepreneurial and innovative life sciences and technology companies, today announced that aggregate revenue of its partner companies for the three months ended September 30, 2010 was $109.6 million, up 73% from $63.4 million for the same partner companies in the same period of 2009.

3 Nov 2010

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

A team of scientists from Japan and the University of California, San Diego School of Medicine have created a new mouse model that confirms that mutations of a protein called beta-synuclein promote neurodegeneration. The discovery creates a potential new target for developing treatments of diseases like Parkinson's and Alzheimer's.

3 Nov 2010

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

For patients with the most common form of hepatitis C being treated for the first time, the addition of an investigational hepatitis C-specific protease inhibitor called telaprevir to the current standard therapy markedly improved their sustained viral response (SVR or viral cure) rate.

3 Nov 2010

Impax third quarter net income increases from $6.7 million to $75.2 million

Impax Laboratories, Inc. today reported adjusted net revenue in the third quarter of 2010, excluding the effect of a change in accounting for revenue received under the Company's Strategic Alliance Agreement with Teva, increased $42.6 million to $107.6 million compared to the prior year period, driven by sales of generic Adderall XR for which there were no sales in the third quarter of 2009, as well as increased sales of the Company's fenofibrate products.

2 Nov 2010

Lactic acid levels in brain linked to aging process

Researchers at Karolinska Institutet have shown that they may be able to monitor the aging process in the brain, by using MRI technique to measure the brain lactic acid levels. Their findings suggest that the lactate levels increase in advance of other aging symptoms, and therefore could be used as an indicator of aging and age-related diseases of the CNS.

2 Nov 2010

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

The Department of Veterans Affairs (VA) has begun distributing disability benefits to Vietnam Veterans who qualify for compensation under recently liberalized rules for Agent Orange exposure.

2 Nov 2010

ArcticDx develops test to determine inherited risk for AMD

Established in 2007 and based in Toronto, ArcticDx has developed a test, Macula Risk-, the first of its kind and specifically designed to determine one's inherited risk for age-related macular degeneration (AMD), the most common form of acquired blindness in the developed world, affecting over 10% of individuals. ArcticDx will use the PBDF investment to undertake studies in support of a planned filing for Food and Drug Administration (FDA) approval for Macula Risk.

2 Nov 2010

New Chicago Sports Concussion Clinic at Rush University provides proper diagnosis for athletes

Concussions, like any injury, need proper assessment and time to heal. Some may brush off an injury to the head, but an injury to the brain may be severe with possible long-term consequences. Athletes or individuals who suffer a bump or blow to the head now can see a physician for assessment within 24 to 48 hours at the new Chicago Sports Concussion Clinic at Rush University Medical Center.

29 Oct 2010

We can consciously control neurons inside our head

Every day our brains are flooded by stimulation - sounds, sights and smells. At the same time, we are constantly engaged in an inner dialogue, ruminating about the past, musing about the future. Somehow the brain filters all this input instantly, selecting some things for long- or short-term storage, discarding others and focusing in on what's most important at any given instant.

29 Oct 2010

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

ACADIA Pharmaceuticals Inc. today announced that it has entered into an agreement with Biovail Laboratories International SRL ("BLS"), a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc., pursuant to which ACADIA and BLS have agreed to conclude their previously established collaboration to develop and commercialize pimavanserin in the United States and Canada.

29 Oct 2010

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Douglas C. Wallace, Ph.D., a pioneer and internationally prominent scientist in the field of human mitochondrial genetics, has joined The Children's Hospital of Philadelphia to continue his investigations into the role of mitochondrial energy in health and disease.

29 Oct 2010

Scientists identify potential new treatment for Nipah and Hendra viruses

Scientists at Weill Cornell Medical College have identified a potential new treatment for the Nipah and Hendra viruses, two lethal and emerging viruses for which there is currently no treatment or vaccine available. The approach could also lead to new therapies for measles, mumps and the flu. The new research appears in today's edition of the prestigious journal Public Library of Science (PLoS) Pathogens.

29 Oct 2010

Researchers develop software tool to study wiring of brains

A team of researchers at the Eindhoven University of Technology has developed a software tool that physicians can use to easily study the wiring of the brains of their patients. The tool converts MRI scans using special techniques to three-dimensional images. This now makes it possible to view a total picture of the winding roads and their contacts without having to operate.

28 Oct 2010

Ipsen reports 8.3% increase in Group sales for first nine months of 2010

Ipsen reported today its sales for the third quarter and the first nine months of 2010.

28 Oct 2010

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Merz to present data on Xeomin clinical studies for cervical dystonia at AAPM&R

Athersys secures three Therapeutic Discovery Project grants

'Phantom' images brain keeps for visual comparisons stored in brain's neural network

Gene fusion prostate cancers susceptible to secondary mutations

New findings show combinational therapy effective for patients with DLBCL lymphoma

Aeolus receives $489,000 grant under QTDP program for two lead compounds

Safeguard Scientifics third quarter aggregate revenue of partner companies increases 73% to $109.6 million

New mouse model confirms mutation of beta-synuclein protein promotes neurodegeneration

Combining telaprevir regimen with standard therapy improves SVR rate in hepatitis C

Impax third quarter net income increases from $6.7 million to $75.2 million

Lactic acid levels in brain linked to aging process

VA begins distributing disability benefits to Vietnam Veterans exposed to Agent Orange

ArcticDx develops test to determine inherited risk for AMD

New Chicago Sports Concussion Clinic at Rush University provides proper diagnosis for athletes

We can consciously control neurons inside our head

ACADIA and BLS enter agreement to conclude pimavanserin collaboration

Prominent scientist in mitochondrial genetics joins Children's Hospital to establish CMEM

Scientists identify potential new treatment for Nipah and Hendra viruses

Researchers develop software tool to study wiring of brains

Ipsen reports 8.3% increase in Group sales for first nine months of 2010

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Fluidics in Modern Healthcare & Medical Device Innovation

Scaling 3D biology: Automation, imaging, and the future of high-throughput research

How does norepinephrine influence anxiety-related behaviours?

Newsletters you may be interested in